BioNTech, Saturn Oil & Gas, TUI - Investments with potential

Good ESG Oil from Canada

The Canadian oil company Saturn Oil & Gas was taken over by a new management team around three years ago and has since been successfully built up. In 2017, the oil price was at times around USD 45.00 per barrel of WTI, only 10% above the current level. In other words, the team around CEO John Jeffrey learned to cope with such conditions early on. In 2019, the company was able to report an annual profit for the first time since its foundation - Saturn Oil & Gas earned almost CAD 1 million. The first quarter of 2020 also closed with a profit.

The crash on the oil market in April 2020 has caused a lot of unrest in the industry, but at the same time it offers opportunities for M&A activities. Saturn Oil & Gas has already announced in news releases that the acquisition of projects is currently favored. It is therefore to be expected that there may be a corresponding development in this context. The oil price of WTI has already stabilized in the past weeks and a price increase of the Saturn Oil & Gas share could also follow. Those who invested in the restructuring three years ago can still look back on a book profit of around 50%. Since then, most other oil producers have recorded a sharp price loss.

On the trail of a vaccine

Biopharmaceutical New Technologies aka. BioNTech, stands for a next generation immunotherapy company that is pioneering the development of therapies for cancer and other serious diseases. BioNTech claims that it combines a variety of modern therapeutic platforms and bioinformatics tools to rapidly advance the development of novel biopharmaceuticals. BioNTech works with world-renowned partners from the pharmaceutical industry, including Genmab, Sanofi, Bayer Animal Health, Roche subsidiary Genentech, Genevant, Fosun Pharma and Pfizer.

The company is also actively engaged in research to develop a vaccine to contain the Corona Pandemic. ""We are pleased to have received FDA fast-track status for two of our vaccine candidates. Together with our partner Pfizer, we will work closely with the FDA to accelerate our clinical development," said Özlem Türeci, Chief Medical Officer of BioNTech. "The FDA's decision to grant fast-track status to these two COVID-19 vaccine candidates is an important milestone in our efforts to develop a safe and effective vaccine against SARS-CoV-2," said Peter Honig, Senior Vice President Global Regulatory Affairs at Pfizer. "We look forward to continuing to work closely with the FDA throughout the clinical development of this program, called Project Lightspeed, to evaluate the safety and efficacy of these vaccine candidates.

In pole position in the travel industry

The travel industry has been severely affected by the restrictions during the Corona Pandemic. Due to its size, the TUI Group was able to rely on government support and maintain its business operations and customer service. Even though the current situation is severely restricting the holiday season, the slow return to a new acceptable normality also seems to be leading to more travel activities by the public again.

A great deal still needs to happen before the share price can return to the level of the fourth quarter of 2019. The decline in economic strength in Europe will lead to more worries and restraint. However, as soon as a vaccine is available on the market or a significant decline in the spread of the Corona Virus becomes apparent, the share is likely to regain the favour of investors.